AMGN—Evenity (romosozumab) BLA on hold due to CV-safety signal in ARCH study (the PDUFA date had been 7/19/17); regulatory submissions in other jurisdictions similarly affected:
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.